UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 9.266

Sortiert nach

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer

Cochrane database of systematic reviews, 2009-07 (3), p.CD004706

2009

Link zum Volltext

Verfügbarkeit prüfen

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Journal of clinical oncology, 2021-02, Vol.39 (6), p.619-630

2021

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

The lancet oncology, 2021-07, Vol.22 (7), p.931-945

2021

Link zum Volltext

Verfügbarkeit prüfen

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Annals of oncology, 2018-12, Vol.29 (12), p.2341-2347

2018

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.653-664

2021

Link zum Volltext

Verfügbarkeit prüfen

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Annals of oncology, 2015-09, Vol.26 (9), p.1883-1889

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer

Journal of clinical oncology, 2019-07, Vol.37 (21), p.1810-1818

2019

Link zum Volltext

Verfügbarkeit prüfen

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Journal of clinical oncology, 2018-09, Vol.36 (26), p.2702-2709

2018

Link zum Volltext

Verfügbarkeit prüfen

Platinum-based drugs for cancer therapy and anti-tumor strategies

Theranostics, 2022-01, Vol.12 (5), p.2115-2132

2022

Link zum Volltext

Verfügbarkeit prüfen

CISPLATIN VERSUS CARBOPLATIN: COMPARATIVE REVIEW OF THERAPEUTIC MANAGEMENT IN SOLID MALIGNANCIES

Critical reviews in oncology/hematology, 2016-06, Vol.102, p.37-46

2016

Link zum Volltext

Verfügbarkeit prüfen

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review

BMC cancer, 2019-11, Vol.19 (1), p.1065-1065, Article 1065

2019

Link zum Volltext

Verfügbarkeit prüfen

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1986-1991

2023

Link zum Volltext

Verfügbarkeit prüfen

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2019-01, Vol.14 (1), p.124-129

2019

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Annals of oncology, 2020-05, Vol.31 (5), p.569-581

2020

Link zum Volltext

Verfügbarkeit prüfen

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

The New England journal of medicine, 2024-03, Vol.390 (10), p.875-888

2024

Link zum Volltext

Verfügbarkeit prüfen

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Annals of oncology, 2013-09, Vol.24 (9), p.2278-2284

2013

Link zum Volltext

Verfügbarkeit prüfen

The state-of-play and future of platinum drugs

Endocrine-related cancer, 2015-08, Vol.22 (4), p.R219-R233

2015

Link zum Volltext

Verfügbarkeit prüfen

Metal-based antitumor compounds: beyond cisplatin

Future medicinal chemistry, 2019-01, Vol.11 (2), p.119-135

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site

Journal of clinical oncology, 2019-03, Vol.37 (7), p.570-579

2019

Link zum Volltext

Verfügbarkeit prüfen

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

Journal of clinical oncology, 2015-06, Vol.33 (17), p.1902-1909

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 9.266

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(8.618)
Mit Volltextzugriff
(7.409)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(9.039)
Science & Technology
(7.472)
Life Sciences & Biomedicine
(7.384)
Female
(6.906)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6.701)
Carboplatin - Administration & Dosage
(5.987)
Oncology
(5.684)
Middle Aged
(5.236)
Aged
(4.579)
Male
(4.561)
Adult
(4.107)
Chemotherapy
(3.233)
Carboplatin
(2.970)
Biological And Medical Sciences
(2.869)
Medical Sciences
(2.864)
Carboplatin - Therapeutic Use
(2.711)
Paclitaxel - Administration & Dosage
(2.547)
Treatment Outcome
(2.483)
Lung Neoplasms - Drug Therapy
(2.396)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(2.147)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(481)
Gynecologic Oncology
(426)
Gan To Kagaku Ryoho
(311)
Annals Of Oncology
(274)
Seminars In Oncology
(255)
Lung Cancer
(240)
Cancer
(236)
Cancer Chemotherapy And Pharmacology
(219)
Anticancer Research
(208)
European Journal Of Cancer
(183)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Platinum-based drugs for cancer therapy and anti-tumor strategies

CISPLATIN VERSUS CARBOPLATIN: COMPARATIVE REVIEW OF THERAPEUTIC MANAGEMENT IN SOLID MALIGNANCIES

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

The state-of-play and future of platinum drugs

Metal-based antitumor compounds: beyond cisplatin

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

Suchergebnisse filtern